10.69
+0.02(+0.19%)
Currency In USD
| Previous Close | 10.67 |
| Open | 10.72 |
| Day High | 10.8 |
| Day Low | 10.52 |
| 52-Week High | 20.56 |
| 52-Week Low | 4.64 |
| Volume | 158,283 |
| Average Volume | 357,433 |
| Market Cap | 134M |
| PE | -1.95 |
| EPS | -5.49 |
| Moving Average 50 Days | 13.59 |
| Moving Average 200 Days | 9.37 |
| Change | 0.02 |
If you invested $1000 in Corbus Pharmaceuticals Holdings, Inc. (CRBP) 10 years ago, it would be worth $210.85 as of December 04, 2025 at a share price of $10.69. Whereas If you bought $1000 worth of Corbus Pharmaceuticals Holdings, Inc. (CRBP) shares 5 years ago, it would be worth $250.94 as of December 04, 2025 at a share price of $10.69.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Corbus Pharmaceuticals Announces Pricing of Public Offering
GlobeNewswire Inc.
Oct 31, 2025 6:40 AM GMT
NORWOOD, Mass., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), an oncology and obesity company, today announced the pricing of an underwritten public offering of 4,744,231 shares
Corbus Pharmaceuticals Announces Proposed Public Offering
GlobeNewswire Inc.
Oct 30, 2025 8:31 PM GMT
NORWOOD, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), an oncology and obesity company, today announced that it plans to offer and sell shares of its common stock or, in l
Corbus Pharmaceuticals Presents CRB-701 Robust Clinical Responses in HNSCC and Cervical Cancers at ESMO25
GlobeNewswire Inc.
Oct 18, 2025 7:00 AM GMT
3.6 mg/kg dose generated ORR of 47.6% in HNSCC, 37.5% in cervical cancer and 55.6% in mUCCRB-701 continues to demonstrate a favorable safety and tolerability profileRegistrational studies planned to start in mid-2026Company to host an HNSCC KOL event